Beta-lactam-induced neutropenia. An old forgotten companion;Neutropenia secundaria a betalactámicos. Una vieja compañera olvidada

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 23, Issue 8, 2005, Pages 485-491

  Peralta, Galo ^a   Sánchez Santiago, María Blanca ^b  

^a HOSPITAL SIERRALLANA   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Adverse drug reaction; Agranulocytosis; Antibiotic; Beta lactam; Neutropenia

Indexed keywords

AMPICILLIN; AZLOCILLIN; BETA LACTAM ANTIBIOTIC; CARBENICILLIN; CEFAPIRIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CLOXACILLIN; IMIPENEM; METICILLIN; MEZLOCILLIN; NAFCILLIN; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIMENTIN;

ANTIBIOTIC THERAPY; FEVER; HUMAN; INFECTIOUS COMPLICATION; NEUTROPENIA; RASH; REVIEW;

EID: 27544473335     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13078841     Document Type: Review

References (69)

1. Fleming A. On the antibacterial action of cultures of penicillium with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol. 1929;10:226.
2. Norrby SR. Problems in the evaluation of adverse reactions to b-lactam antibiotics. Rev Infect Dis. 1986;8 Suppl 3:358-67.
3. Alanis A, Weinstein AJ. Adverse reactions associated with the use of oral penicillins and cephalosporins. Med Clin North Am. 1983;67:113-29.
4. Smith CR. Cefotaxime and cephalosporins: adverse reactions in perspective. Rev Infect Dis. 1982;4 Suppl:481-8.
5. Gorevic PD. Drug-induced autoimmune disease. En: Kaplan A, editor. Allergy. Philadelphia: WB Saunders; 1997. p. 620-43.
6. Spain DM, Clark TB. A case of agranulocytosis occurring during the course of penicillin therapy. Ann Intern Med. 1946;25:732-3.
7. Wong BB, Ko GJ. Neutropenia in patients receiving long-term cefepime therapy for osteomyelitis. Am J Health Syst Pharm. 2003;60:2229-32.
8. Peralta FG, Sanchez MB, Roiz MP, Pena MA, Tejero MA, Arjona R. Incidence of neutropenia during treatment of bone-related infections with piperacillin-tazobactam. Clin Infect Dis. 2003;37:1568-72.
9. Taniuchi S, Masuda M, Yamamoto A, Hasui M, Tsuji S, Takahashi H, et al. Two cases of autoimmune neutropenia possibly induced by beta-lactam antibiotics in infants. J Pediatr Hematol Oncol. 2000;22:533-8.
10. Bibbo C, Barbieru RA, Deitch EA, Brolin RE. Neutropenic enterocolitis in a trauma patient during antibiotic therapy for osteomyelitis. J Trauma. 2000;49:760-63.
11. Andres E, Maloisel F. Antibiotic-induced agranulocitosis: a monocentric study of 21 cases. Arch Intern Med. 2001;161:2619.
12. Singh N, Yu VL, Mieles LA, Wagener MM. β-Lactam antibiotic-induced leukopenia in severe hepatic dysfunction: risk factors and implications for dosing in patients with liver disease. Am J Med. 1993;94:251-6.
13. Yow MD, Taber LH, Barrett FF, Mintz A, Blankinship R, Clark E, et al. A ten year assessment of methicillin-associated side effects. Pediatrics. 1976;58:329-34.
14. Neu HC. Safety of Cefepime: a new extended-spectrum parenteral cephalosporin. Am J Med. 1996;100 Suppl 6A:68-75.
15. Olaison L, Alestig K. A prospective study of neutropenia induced by high doses of β-lactam antibiotics. J Antimicrob Chemother. 1990;25:449-53.
16. Olaison L, Belin L, Hogevik H, Alestig K. Incidence of beta-lactam-induced delayed hypersensitivity and neutropenia during treatment of infective endocarditis. Arch Intern Med. 1999;159:607-15.
17. Reichardt P, Handrick W, Linke A, Schille R, Kiess W. Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment: a retrospective analysis in 38 children with cystic fibrosis. Infection. 1999;27:355-6.
18. Nahata MC, DeBolt SL, Powell DA. Adverse effects of methicillin, nafcillin and oxacillin in pediatric patients. Dev Pharmacol Ther. 1982;4:117-23.
19. Lang R, Lishner M, Ravid M. Adverse reactions to prolonged treatment with high doses of carbenicillin and ureidopenicillins. Rev Infect Dis. 1991;13:68-72.
20. Kumar K, Kumar A. Reversible neutropenia associated with ampicillin therapy in pediatric patients. Drug Intell Clin Pharm. 1981;15:802-6.
21. Kitzing W, Nelson JD, Mohs E. Comparative toxicities of methicillin and nafcillin. Am J Dis Child. 1981;135:52-5.
22. Neftel KA, Wälti M, Spengler H, Von Fellen A, Weitzman SA, Burgi H, et al. Neutropenia after penicillins: toxic or immune-mediated. Klin Wochenschr. 1981;59:877-88.
23. Kancir LM, Tuazon CU, Cardella TA, Sheagren JN. Adverse reactions to methicillin and nafcillin during treatment of serious Staphylococcus aureus infections. Arch Intern Med. 1978;138:909-11.
24. Murphy MF, Metcalfe P, Grint PC, Green AR, Knowles S, Amess JA, et al. Cephalosporin-induced immune neutropenia. Br J Haematol. 1985;59:9-14.
25. Neftel KA, Hauser SP, Muller MR, Walti M. Cephalosporin-induced neutropenia. Br J Haematol. 1986;62:394-7.
26. Snavely SR, Helzberg JH, Bodensteiner DC, Plapp FV, Davis JW, Hodges GR. Profound neutropenia associated with benzylpenicillin. South Med J. 1983;76:1299-302.
27. Clotet B, Martínez Vea A, Rubies-Prat J, Foz Sala M. Cloxacillin-induced leukopenia. Arch Intern Med. 1985;145:1531.
28. Gatell JM, Rello J, Miró JM, Martínez JA, Soriano E, SanMiguel García J. Cloxacillin-induced neutropenia. J Infect Dis. 1986;154:372.
29. Burton IE, Moussa KM, Sanders PA. Agranulocytosis in rheumatoid arthritis associated with long-term flucloxacillin for staphylococcal osteomyelitis. Acta Haematol. 1995;94:196-8.
30. Vidal-Pan C, González-Quintela A, Román-García J, Millán I, Martín-Martín F, Moya-Mir M. Cephapirin-induced neutropenia. Chemotherapy. 1989;35:449-53.
31. Levison ME, Bran JL, Jepson JH, Kaye D. Neutropenia associated with cephapirin therapy. Antimicrob Agents Chemother. 1972;1174-6.
32. Baciewicz AM, Skiest DJ, Weinshel EL. Ceftriaxone-associated neutropenia. Drug Intell Clin Pharm. 1988;22:826-7.
33. Burgaleta C, Parras F, Hermida JM. Neutropenia secondary to cefotaxime use. Enferm Infecc Microbiol Clin. 1989;7:364-7.
34. Farinas MC, De Vega T, Garmendia J, González-Macías J. Severe neutropenia in a patient treated with imipenem/cilastatin. Eur J Clin Microbiol Infect Dis. 1993;12:303-4.
35. Calandra GB, Wang C, Aziz M, Brown KR. The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients. J Antimicrob Chemother 1986;18 Suppl E:193-202.
36. Dallai MM, Czachor JS. Aztreonam-induced myelosuppression during treatment of Pseudomonas aeruginosa pneumonia. DICP. 1991;25:594-7.
37. Dahlgren AF. Two cases of possible Cefepime-induced neutropenia. Am J Health Syst Pharm. 1997;54:2621-2.
38. Ruiz-Irastorza G, Barreiro G, Aguirre C. Reversible bone marrow depression by high-dose piperacillin/tazobactam. Br J Haematol. 1996;95:611-2.
39. Behbahani R, Kostman JR. Hypersensitivity reaction during prolonged use of piperacillin/tazobactam in treatment of osteomyelitis. Ann Pharmacother. 1995;29:936-7.
40. Gerber L, Wing EJ. Life-threatening neutropenia secondary to piperacillin/tazobactam therapy. Clin Infect Dis. 1995;21:1047-8.
41. Schmid L, Heit W, Flury R. Agranulocytosis associated with semisynthetic penicillins and cephalosporines: review of 7 cases. Blut. 1984;48:11-8.
42. Wiholm BE, Emanuelsson S. Drug-related blood dyscrasias in a Swedish reporting system, 1985-1994. Eur J Haematol Suppl. 1996;60:42-6.
43. Van der Klauw MM, Wilson JHP, Stricker BH. Drug-associated agranulocytosis: 20 years of reporting in the Netherlands (1974-1994). Am J Hematol. 1998;57:206-11.
44. Weitzman SA, Stossel TP. Drug-induced immunological neutropenia. Lancet. 1978;1(8073):1068-72.
45. Anti-infective drug use in relation to the risk of agranulocytosis and aplastic anemia. A report from the International Agranulocytosis and Aplastic Anemia Study. Arch Intern Med. 1989;149:1036-40.
46. Editorial. Antibiotic-induced neutropenia. Lancet. 1985;2:814.
47. Neftel KA, Hauser SP, Müller MR. Inhibition of granulopoiesis in vivo and in vitro by β-lactam antibiotics. J Infect Dis. 1985;152:90-8.
48. Kirkwood CF, Smith LL, Rustagi PK, Schentag JJ. Neutropenia associated with beta-lactam antibiotics. Clin Pharm. 1983;2:569-78.
49. Schmid L, Heit W, Flury R. Agranulocytosis associated with semisynthetic penicillins and cephalosporins. Report of 7 cases. Blut. 1984;48:11-8.
50. Do UH, Neftel KA, Spadari S, Hubscher U. Betalactam antibiotics interfere with eukaryotic DNA-replication by inhibiting DNA polymerase alpha. Nucleic Acids Res. 1987;15:10495-506.
51. Charak BS, Louie R, Malloy B, Twomey P, Mazumder A. The effect of amphotericin B, aztreonam, imipenem and cephalosporins on the bone marrow progenitor cell activity. J Antimicrob Chemother. 1991;27:95-104.
52. Rouveix B, Lassoued K, Vittecoq D, Regnier B. Neutropenia due to β-lactamine antibodies. BMJ. 1983;287:1832-4.
53. Garraty G. Immune cytopenia associated with antibiotics. Transfus Med Rev. 1993;7:255-67.
54. Murphy MF, Riordan T, Minchinton RM, Chapman JF, Amess JA, Shaw EJ, et al. Demonstration of an immune-mediated mechanism of penicillin-induced neutropenia and thrombocytopenia. Br J Haematol. 1983;55:155-60.
55. Desgrandchamps D, Schnyder C. Severe neutropenia in prolonged treatment with orally administered Augmentin® (amoxicillin/clavulanic acid). Infection 1987;15:44-5.
56. Perry CM, Markham A. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs. 1999;57:805-43.
57. Siami G, Christou N, Eiseman I, Tack KJ. Severe skin and soft tissue infections study group. Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrob Agents Chemother. 2001;45:525-31.
58. Graham DR, Lucasti C, Malafaia O, Nichols RL, Holtom P, Pérez NQ, et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis. 2002;34:1460-8.
59. Parry MF, Neu NH. The safety and tolerance of mezlocilin. J Antimicrob Chemother. 1982;9 Suppl A:273-80.
60. Reichman N, Raz R, Schlaeffer F, Elías M, Flatau E. Ceftriaxone-induced agranulocytosis. Isr J Med Sci. 1993;29:52-4.
61. Gavalda J, Miró J, Torres C, De la Torre Cisneros J, Muñoz P, Peña C, et al. Efficacy of ampicillin (A) plus ceftriaxone (Ctr) or cefotaxime (Cx) in treatment of endocarditis due to Enterococcus faecalis [abstract L1342]. En: Programs and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington: American Society for Microbiology, 2001. p. 3.
62. Le T, Bayer AS. Combination antibiotic therapy for infective endocarditis. Clin Infect Dis. 2003;36:615-21.
63. Hoffman-Terry ML, Fraimow HS, Fox TR, Swift BG, Wolf JE. Adverse effects of outpatient parenteral antibiotic therapy. Am J Med. 1999;106:44-9.
64. Pill MW, O'Neill CV, Chapman MM, Singh AK. Suspected interstitial nephritis induced by piperacillin-tazobactam. Pharmacotherapy. 1997;17:166-9.
65. Beauchesne MF, Shalansky SJ. Nonchemotherapy drug-induced agranulocytosis: a review of 118 patients treated with colony-stimulating factors. Pharmacotherapy. 1999;19:299-305.
66. Teppler H, Gesser RM, Friedland IR, Woods GL, Meibohm A, Herman G, et al. Safety and tolerability of ertapenem. J Antimicrob Chemother. 2004;53 Suppl 2:75-81.
67. Wilson C, Greenhood G, Remington JS, Vosti KL. Neutropenia after consecutive treatment courses with nafcillin and piperacillin. Lancet. 1979;972:1150.
68. Kaaja R, Valtonen W. Leucopenia associated with beta-lactam antibiotic therapy. Acta Med Scand. 1984;216:531-4.
69. Kibbler CC, Prentice HG, Sage RJ, Hoffbrand AV, Brenner MK, Noone P. Do double-beta-lactam combinations prolong neutropenia in patients undergoing chemotherapy or bone marrow transplantation for hematological disease? Antimicrob Agents Chemother. 1989;33:503-7.